

Date: October 1st, 2014

Dear Customers,

Re: Announcement of Business Transfer from Sumitomo Corporation to
Summit Pharmaceuticals International Corporation

We, Summit Pharmaceuticals International Corporation ("SPI"), are pleased to announce that all the trading business of API & Fine Chemicals products handled by Medical Science Dept of Sumitomo Corporation ("SC", our parent company) has been transferred to us as of October 1st, 2014.

By integrating the transferred business with existing lines, SPI shall provide more high-profile service for trading business of API & Fine Chemicals products in the global market.

For more details on this business transfer, please contact following attention.

Summit Pharmaceuticals International Corporation
TEL : +81-3-3536-8611
Email : info@summitpharma.co.jp

Your kind understanding on this business transfer would be highly appreciated.

Sincerely yours,

Yoshiki Terawaki
President
Summit Pharmaceuticals International Corporation